Paper Details

  1. Home
  2. Paper Details

Randomized trial of lamivudine versus hepatitis B immunoglobulin for long-term prophylaxis of hepatitis B recurrence after liver transplantation.

Author: AnschuetzG, AtkinsM, BarrettC A, BassendineM, BurraP, CaccamoL, IemmoloR M, LopesA R, NaoumovN V, O'GradyJ G, PortmannB C, WilliamsR, de ManR A

Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.

Overview

Substitution of hepatitis B immunoglobulin (HBIg) with lamivudine was effective in preventing hepatitis B virus (HBV) recurrence in low-risk liver transplant recipients, offering a convenient and cost-effective alternative for long-term HBV prophylaxis.
Paper Details　
Original Abstract of the Article :
BACKGROUND/AIMS: The long-term prophylaxis of hepatitis B after liver transplantation requires further optimization. In a randomized trial we investigated a regimen where the initially given hepatitis B immunoglobulin (HBIg) is replaced by long-term lamivudine treatment. METHODS: Twenty-four liver ...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1016/s0168-8278(01)00039-3

データ提供：米国国立医学図書館（NLM）

Lamivudine Versus Hepatitis B Immunoglobulin for Long-Term Prophylaxis After Liver Transplantation

This study compares the effectiveness of lamivudine, an antiviral medication, and hepatitis B immunoglobulin (HBIg) in preventing the recurrence of hepatitis B infection after liver transplantation. Imagine a desert, and hepatitis B infection, like a persistent sandstorm, can cause serious damage to the liver. This study, like a team of transplant surgeons, seeks to find the best way to protect patients from this threat.

Lamivudine: A Promising Alternative for Long-Term Prophylaxis

The study found that lamivudine, like a sturdy camel, was effective in preventing hepatitis B recurrence in liver transplant recipients who were initially treated with HBIg. The results demonstrated that lamivudine offered a convenient and cost-effective alternative to HBIg for long-term prophylaxis. The study also noted that lamivudine was generally well-tolerated and associated with normal graft function in patients who continued the medication after the study.

A Safe Haven in the Desert of Hepatitis B: Long-Term Prophylaxis

This research provides valuable insights into the management of hepatitis B after liver transplantation. It's like finding a safe haven in the desert of hepatitis B, offering a promising alternative for long-term prophylaxis.

Dr.Camel's Conclusion

This study highlights the effectiveness of lamivudine as a long-term prophylaxis for hepatitis B recurrence after liver transplantation. Imagine it as a well-stocked oasis, providing a safe and effective solution for protecting the liver after a transplant.

Date :
  1. Date Completed 2002-01-14
  2. Date Revised 2019-08-17
Further Info :

Pubmed ID

11451173

DOI: Digital Object Identifier

10.1016/s0168-8278(01)00039-3

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.